BPC-157 vs CJC-1295

People do, and the mechanisms don't obviously conflict - BPC-157 acts on tissue repair and angiogenesis while CJC-1295 hits the GHRH receptor. The theoretical case is that higher IGF-1 from CJC-1295 supports the tissue healing BPC-157 is claimed to promote. There is no human trial data on the combination. Both are research chemical status in the US, so stacking means stacking your unknown-unknowns. Legitimate clinics that used to run CJC-1295 protocols almost always paired it with ipamorelin, not BPC-157.

CJC-1295 has more published human pharmacokinetic data, mostly from small trials demonstrating GH and IGF-1 elevation after injection. BPC-157 has three small pilot studies in humans, none randomized or placebo-controlled. Neither has the kind of large Phase 3 trials you would see for an FDA approved drug. The rodent literature for both is extensive, but animal-to-human translation is not automatic. On evidence quality, CJC-1295 is slightly ahead, though both are far from the clinical standard.

Neither is legal for human consumption. Both hit FDA Category 2 in September 2023, removing the only legitimate pharmacy pathway that existed. Research chemical suppliers still sell them labeled not for human consumption, which is the legal fiction that keeps the market running. Possession is not criminalized federally, but no compounding pharmacy can legally make either one for a patient. The February 2026 FDA reclassification review may change status for one or both, but no changes have taken effect.

Not really. If you want a legitimate clinical program for GH optimization, sermorelin (FDA-approved history, off-label through 503A pharmacies) and compounded tesamorelin (FDA approved for HIV lipodystrophy, off-label for adult anti-aging) are the legal pathways. Both are GHRH analogs like CJC-1295 but come with actual pharmacy supply chains, medical supervision, and no FDA Category 2 classification. CJC-1295 offered longer half-life in theory, but that advantage is moot when you cannot legally obtain it.

BPC-157 works via Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth. CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. They differ in FDA approval status, efficacy data, and cost.

BPC-157 typically costs $50 - $120/mo, while CJC-1295 costs $35 - $70/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

BPC-157 is not FDA-approved (Category 2 (pending reclassification)). CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of BPC-157 include Injection site discomfort, Mild headache, Dizziness. Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.